Scribe Therapeutics: Funding, Investors & Team (Oct 2026)
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.
Scribe Therapeutics has raised $25.0M across 2 funding rounds on record, the most recent an undisclosed round of $25.0M announced in Jun 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Scribe Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Scribe Therapeutics Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Scribe Therapeutics announced an undisclosed round in May 2023; the amount was not disclosed.
3.1 years later, an undisclosed round of $25.0M was announced in Jun 2026.
Scribe Therapeutics Founders and Leadership Team
Contact details for the Scribe Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Scribe Therapeutics Funding Compared to Other Biotechnology Startups
Scribe Therapeutics' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Scribe Therapeutics in Biotechnology and Alameda
Companies Similar to Scribe Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Scribe Therapeutics Funding FAQs
What does Scribe Therapeutics do?
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.
How much funding has Scribe Therapeutics raised?
Scribe Therapeutics has raised $25.0M across 2 rounds on record. The most recent is an undisclosed round of $25.0M announced in Jun 2026.
When did Scribe Therapeutics last raise funding?
Scribe Therapeutics' most recent funding round on record is an undisclosed round of $25.0M, announced in Jun 2026.
Who is the CEO of Scribe Therapeutics?
Benjamin Oakes is listed as CEO at Scribe Therapeutics.
Where is Scribe Therapeutics headquartered?
Scribe Therapeutics is based in Alameda, California, United States.
How many employees does Scribe Therapeutics have?
Scribe Therapeutics is in the 51-100 employee band.
How does Scribe Therapeutics' funding compare to other Biotechnology startups?
Scribe Therapeutics' latest round of $25.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Scribe Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Scribe Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.